Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cyclacel Pharmaceuticals Inc
Change in Working Capital
Cyclacel Pharmaceuticals Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
Change in Working Capital
-$9.1m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-74%
|
CAGR 10-Years
-22%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Working Capital
-$2.4B
|
CAGR 3-Years
-109%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Working Capital
-$3.9B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Working Capital
$10B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Working Capital
-$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-86%
|
CAGR 10-Years
-30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Working Capital
$532.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
9%
|
|
Cyclacel Pharmaceuticals Inc
Glance View
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.
See Also
What is Cyclacel Pharmaceuticals Inc's Change in Working Capital?
Change in Working Capital
-9.1m
USD
Based on the financial report for Jun 30, 2025, Cyclacel Pharmaceuticals Inc's Change in Working Capital amounts to -9.1m USD.
What is Cyclacel Pharmaceuticals Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
-22%
The average annual Change in Working Capital growth rates for Cyclacel Pharmaceuticals Inc have been -68% over the past three years , -74% over the past five years , and -22% over the past ten years .
